Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04666636 · ClinicalTrials.gov registry record · Phase 2

Mechanisms for Activation of Beige Adipose Tissue in Humans

A Phase 2 study of PreDiabetes, sponsored by Philip Kern.

Recruiting
Registry status
Phase 2
Development phase
65
Enrollment target
1
Study location

NCT04666636 is a Phase 2 study of PreDiabetes that is actively recruiting participants, run by Philip Kern. The registered enrollment target is 65 participants, below the 690-participant average among 89 other PreDiabetes trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04666636, a Phase 2 study of PreDiabetes, is actively recruiting participants, sponsored by Philip Kern.

RECRUITING
Registry status
Phase 2
Development phase
65 participants
Enrollment target
1
Study location

Study Summary

Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients

Conditions Studied

PreDiabetes

Interventions

  • DRUG Placebo
  • DRUG Mirabegron 50 MG
  • DRUG Mirabegron
  • DRUG Mirabegron 100 mg

Study Locations (1)

Kentucky

  • University of Kentucky - Lexington

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2020-12-07
Est. Completion 2026-12-01
Phase Phase 2

Sponsor

Philip Kern

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04666636

The ClinicalTrials.gov registry entry for NCT04666636 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 690-participant average among 89 other PreDiabetes trials with a reported enrollment target (91% lower). The listed sponsor is Philip Kern, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with PreDiabetes appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT04666636 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.

Frequently Asked Questions

What is clinical trial NCT04666636 about?

NCT04666636 is a clinical study titled "Mechanisms for Activation of Beige Adipose Tissue in Humans". Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients

What is the current status of trial NCT04666636?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2020-12-07. Estimated completion is 2026-12-01.

What conditions does trial NCT04666636 study?

This clinical trial studies the following conditions: PreDiabetes.

What interventions are being tested in trial NCT04666636?

The interventions under investigation include: Placebo (DRUG), Mirabegron 50 MG (DRUG), Mirabegron (DRUG), Mirabegron 100 mg (DRUG).

Who is sponsoring clinical trial NCT04666636?

This trial is sponsored by Philip Kern, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04666636 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for PreDiabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

PreDiabetes

All registered trials for this condition

Kentucky

All trials with a study site in Kentucky

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.